Effect of plasma C-reactive protein levels in modulating the risk of coronary heart disease associated with small, dense, low-density lipoproteins in men (The Quebec Cardiovascular Study)

American Journal of Cardiology

Volumn 91, Issue 5, 2003, Pages 555-558

  St Pierre, Annie C ^b   Bergeron, Jean ^b   Pirro, Matteo ^b   Cantin, Bernard ^b   Dagenais, Gilles R ^b   Després, Jean Pierre ^b   Lamarche, Benoît ^a  

^a LAVAL UNIVERSITY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN; POLYACRYLAMIDE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; RISK;

EID: 0037374480     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)03305-2     Document Type: Article

References (24)

1. Ylitalo R., Jaakkola O., Lehtolainen P., Yla-Herttuala S. Metabolism of modified LDL and foam cell formation in murine macrophage-like RAW 264 cells. Life Sci. 64:1999;1955-1965.
2. Griffin B.A. Lipoprotein atherogenicity an overview of current mechanisms . Proc Nutr Soc. 58:1999;163-169.
3. Dagenais G.R., Robitaille N.M., Lupien P.J., Christen A., Gingras S., Moorjani S., Meyer F., Rochon J. First coronary heart disease event rates in relation to major risk factors Québec Cardiovascular Study . Can J Cardiol. 6:1990;274-280.
4. Lamarche B., Després J.P., Moorjani S., Cantin B., Dagenais G.R., Lupien P.J. Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Québec Cardiovascular Study). Am J Cardiol. 75:1995;1189-1195.
5. Moorjani S., Dupont A., Labrie F., Lupien P.J., Brun L.D., Gagné C., Giguère M., Bélanger A. Increase in plasma high density lipoprotein concentration following complete androgen blockage in men with prostatic carcinoma. Metabolism. 36:1987;244-250.
6. 2 precipitation procedures for estimating cholesterol in high-density lipoproteins. Clin Chem. 24:1978;323-338.
7. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18:1972;499-502.
8. Laurell C.B. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Ann Biochem. 15:1966;45-52.
9. Pirro M., Bergeron J., Dagenais G.R., Bernard P.M., Cantin B., Despres J.P., Lamarche B. Age and duration of follow-up as modulators of the risk of ischemic heart desease associated with high plasma C-reactive protein levels in men. Arch Intern Med. 161:2001;2474-2480.
10. St-Pierre A.C., Ruel L., Cantin B., Dagenais G.R., Després J.P., Lamarche B. Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation. 104:2001;2295-2299.
11. Tracy R.P. Inflammation in cardiovascular disease cart, horse, or both? Circulation. 97:1998;2000-2002.
12. Tracy R.P. Inflammation markers and coronary heart disease. Curr Opin Lipidol. 10:1999;435-441.
13. Zhang Y.X., Cliff W.J., Schoefl G.I., Higgins G. Coronary C-reactive protein distribution its relation to development of atherosclerosis . Atherosclerosis. 145:1999;375-379.
14. Cermak J., Key N.S., Bach R.R., Balla J., Jacob H.S., Vercellotti G.M. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood. 82:1993;513-520.
15. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 342:2000;836-843.
16. de Beer F.C., Soutar A.K., Baltz M.L., Trayner I.M., Feinstein A., Pepys M.B. Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein. J Exp Med. 156:1982;230-242.
17. Danesh J., Whincup P., Walker M., Lennon L., Thomson A., Appleby P., Gallimore J.R., Pepys M.B. Low grade inflammation and coronary heart disease prospective study and updated meta-analyses . BMJ. 321:2000;199-204.
18. Zeller J.M., Sullivan B.L. C-reactive protein selectively enhances the intracellular generation of reactive oxygen products by IgG-stimulated monocytes and neutrophils. J Leukocyte Biol. 52:1992;449-455.
19. Murphy T.M., Baum L.L., Beaman K.D. Extrahepatic transcription of human C-reactive protein. J Exp Med. 173:1991;495-498.
20. Mookerjea S., Francis J., Hunt D., Yang C.Y., Nagpurkar A. Rat C-reactive protein causes a charge modification of LDL and stimulates its degradation by macrophages. Arterioscler Thromb. 14:1994;282-287.
21. Bhakdi S., Torzewski M., Klouche M., Hemmes M. Complement and atherogenesis binding of CRP to degraded, nonoxidized LDL enhances complement activation . Arterioscler Thromb Vasc Biol. 19:1999;2348-2354.
22. Navab M., Berliner J.A., Watson A.D., Hama S.Y., Territo M.C., Lusis A.J., Shih D.M., Van Lenten B.J., Frank J.S., Demer L.L., Edwards P.A., Fogelman A.M. The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. PG-831-42. Arterioscler Thromb Vasc Biol. 16:1996;831-842.
23. Morel D.W., Hessler J.R., Chisolm G.M. Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. J Lipid Res. 24:1983;1070-1076.
24. Quinn M.T., Parthasarathy S., Fong L.G., Steinberg D. Oxidatively modified low density lipoproteins a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. PG . Proc Natl Acad Sci USA. 84:1987;2995-2998.